year left
short interest float
fortress biotech fbio biopharmaceut compani acquir develop
commerci therapeut asset identifi promis treatment opportun
busi develop team asset develop primarili subsidiari compani
sometim refer fortress compani fortress super-major vote share
current fortress compani mean maintain full control
sharehold vote abil appoint major board director
compani addit fortress signific stock ownership subsidiari compani
fortress fortress compani diversifi pipelin commerci asset
double-digit number clinic preclin stage asset candid cover
plethora technolog car-t gene therapi target therapi immunotherapi cell
therapi diseas area includ cancer al amyloidosi cmv autoimmun diseas
organ transplant other fortress led experienc manag team
track record success develop therapeut
point discuss
fortress divers pipelin across multipl area
technolog fortress fortress compani current commerci
asset double-digit number clinic pre-clin stage asset candid
come broad array drug develop platform car-t gene therapi target
therapi immunotherapi cell therapi evalu sever therapeut area
addit fortress team scientif financi expert
assess potenti product candid in-licens acquisit within industri academ
institut govern institut thu expect addit product candid
develop futur fortress level within exist fortress compani
new subsidiari compani overal fortress diversifi pipelin mitig
risk typic associ smaller biopharma compani focus limit
number technolog diseas area
avenu begin second phase data assess iv tramadol acut
helocyt complet phase ii trial assess triplex cmv control
mustang file ind multi-cent trial
checkpoint clinic updat phase trial
late cyprium file nda menk diseas
earli caelum initi phase ii/ studi assess al
checkpoint initi phase global registr trial
checkpoint initi phase studi mutant egfr
analyst certif disclosur pleas see page
steadi revenu fortress compani increas runway current fortress
biopharmaceut subsidiari publicli trade exchang other plan go public
futur annual fortress receiv consult fee depend subsidiari
net asset level fully-dilut outstand equiti annual fortress compani fortress
also elig futur net sale fortress compani well gross amount
equiti debt financ fee partial off-set oper cost prevent dilut increas cash
runway fortress addit fortress maintain super-major vote share fortress compani
mean fortress retain control sharehold vote abil appoint major board
director compani notabl fortress strive reduc use cash subsidiari instead
provid network investor may invest fortress compani meet financi need
fortress fortress compani util effici drug develop strategi drug develop
capit intens time-consum process requir care strateg plan manag
enhanc execut fortress play key role development progress product candid within
fortress compani includ provid fund manag servic regard busi develop
account financ clinic trial execut scientif affair manufactur legal process allow
effici drug develop within fortress compani may result substanti cost save throughout
development process
current valuat attribut limit valu fortress privat subsidiari fortress
ownership subsidiari compani public fortress compani fortress equiti ownership
checkpoint
avenu atxi nation hold corpor nhld
origo acquisit corpor oacq notabl amount privat subsidiari sum-
of-the-part sotp analysi indic fortress cumul equiti valu public subsidiari compani
roughli million may howev million market cap cash cash equival cash
deposit restrict cash million debt million appear much valu current
given fortress privat subsidiari pipelin fortress fortress compani
advanc privat fortress compani becom publicli trade entiti expect
could notabl valu gener sharehold fortress biotech compani also like acquir new
asset develop fortress level within exist fortress compani new subsidiari
fortress manag track record success fortress led dr lindsay rosenwald chairman
presid ceo michael weiss execut vice chairman strateg develop
well known biotech entrepreneur launch led sever biotech compani bring sever
clinic develop approv acquisit notabl compani includ cougar biotech acquir johnson
 johnson billion chelsea therapeut acquir lundbeck million
keryx biopharmaceut kerx market cap -auryxia approv chronic kidney
diseas invest result substanti return investor highlight potenti upsid
fortress fortress compani addit experienc manag recruit run
fortress compani ensur proper develop launch pipelin candid take place
full year result shown figur full year fortress record
net loss million per share compar net loss million per share
fortress research develop cost million million relat fortress
compani increas million full year million relat
fortress compani gener administr expens million million
relat fortress compani compar million million relat fortress
compani septemb fortress acquir control interest nation secur corpor
nhld independ brokerag financi firm fortress consolid nation asset acquir
liabil assum revenu one quarter lag net revenu fortress total million compar
million million revenu attribut nation million fortress
research develop expens
gener administr expens
first quarter tress net revenu million million period
million revenu relat fortress million nation hold
research develop expens quarter million compar million
gener administr expens million million million
million relat fortress compani respect net loss million
per share march compani consolid cash cash equival short-term invest
restrict cash million
tabl content
scientif train identifi promis product candid in-licens
fortress foster acceler drug develop subsidiari compani
fortress subsidiari synergi among support growth
fortress busi model provid diversifi portfolio investor
risk invest
fortress biotech fbio biopharmaceut compani acquir develop commerci
therapeut asset identifi promis treatment opportun busi develop team asset
develop primarili subsidiari compani sometim refer fortress compani fortress super-
major vote share biopharma fortress compani mean maintain full control
sharehold vote abil appoint major board director compani fortress
fortress compani current commerci asset double-digit number clinic pre-
clinic stage asset candid cover plethora technolog car-t gene therapi target therapi
immunotherapi cell therapi diseas area includ cancer al amyloidosi cmv autoimmun diseas organ
transplant other development pipelin fortress subsidiari shown figur
fortress team scientif financi expert assess potenti product candid in-
licens acquisit within industri academ institut govern institut current fortress
biopharmaceut subsidiari publicli trade exchang other plan go public
futur annual fortress receiv consult fee depend subsidiari net
asset level fully-dilut outstand capit subsidiari fortress also elig
futur net sale fortress compani exclud journey consolid revenu
well gross amount equiti debt financ fee partial off-set oper cost
increas cash runway fortress
glioblastoma multiform breast cancer
metastat brain
cmv allogen stem cell transplant
cmv kidney transplant
cmv liver transplant
cmv allogen stem cell transplant
cmv/hiv co-infect patient art
ahu pnh
fortress use busi model aim acquir develop commerci therapeut candid across rang
diseas area stage develop fortress level fortress compani fortress
dedic team scientif financi medic expert identifi new in-licens
acquisit opportun academ institut corpor entiti govern health organ
acquir product candid develop within fortress one exist subsidiari new subsidiari
compani fortress retain major vote control fortress compani establish around one
product candid typic therapeut focu car-t gene therapi valid cancer target cell
therapi experienc manag also recruit run fortress compani approach repres uniqu
model fortress abl develop broad rang therapeut candid reduc expenditur
notabl event clinic trial failur impact fortress fraction subsidiari focus
develop product fortress well diversifi own fraction asset current fortress
subsidiari fortress compani commerci asset double-digit number clinic pre-clin
stage candid develop
scientif train identifi promis product candid in-licens fortress use effici
extens due-dilig process acquisit product candid shown figur
describ detail
figur identif due-dilig process new product candid
identifi product candid scientif financi expert fortress identifi potenti product
candid three primari sourc academ center corpor entiti govern health
organ product candid screen regardless indic type therapi particular
fortress seek identifi treatment may previous demonstr encourag preclin clinic
result current advanc reason lack fund expertis resourc etc
due-dilig due-dilig process includ obtain expert view key opinion leader
field assess clinic data product candid current standard care analyz total market
opportun confirm intellectu properti protect compar safeti toler efficaci
compet drug diseas area togeth analysi assess scientif promis market
potenti help guid fortress decis in-licensing/acquir product candid
in-licens fortress exercis variou method deal structur gain access identifi product
arrang joint ventur co-promot public/priv financ option agreement product
candid interest deal agre upon fortress owner product candid
compani acquir right treatment develop fortress level within exist
fortress compani creat new subsidiari fortress remain dedic licens candid
subsidiari compani provid follow support financi regulatori legal scientif
manufactur develop
fortress foster acceler drug develop subsidiari compani drug develop capit
intens time-consum process requir care strateg plan manag enhanc
execut fortress play key role development progress product candid within fortress
compani previous mention shown figur includ provid fund manag
manufactur legal experienc board member process allow effici drug develop within
subsidiari compani may result substanti cost save throughout development process addit
fortress maintain super-major vote share fortress compani mean fortress retain control
sharehold vote abil appoint major board director compani
figur fortress fund manag support subsidiari compani
fortress subsidiari synergi among support growth depict figur
exampl synergi among helocyt within fortress network
synergi particularli crucial area immuno-oncolog sinc clinic trial frequent combin
treatment checkpoint inhibitor merck nyse keytruda pembrolizumab bristol-my
squibb nyse opdivo nivolumab therefor futur oncolog clinic trial may util cost synergi
combin treatment checkpoint inhibitor
potenti out-licens strategi fortress subsidiari fortress compani plan either out-licens
asset bring market independ includ asset develop receiv
fda approv shown figur fortress open out-licens disposit opportun within us
intern potenti deal structur could includ royalti mileston /- up-front payment
method potenti provid sever revenu stream fortress fortress compani
fortress busi model provid diversifi portfolio investor fortress hold super-major
vote power fortress compani strive reduc use fortress cash instead fortress
provid network investor may invest fortress compani meet financi need busi
model fortress gain valu fortress compani four-fold
fortress receiv fully-dilut outstand equiti annual fortress compani
fortress receiv royalti net sale fortress compani exclud journey
consolid revenu
fortress receiv annual consult fee fee increas million annual
subsidiari hold net asset greater million begin given calendar year
fortress receiv amount subsidiari common stock equal gross amount equiti
debt financ rais fortress compani
setup provid busi model fortress maintain vote control subsidiari receiv
annual revenu provid diversifi portfolio investor fortress model also incentiv fortress
manag subsidiari manag team develop commerci asset effici
journey medic corpor privat form octob journey focus develop acquir
licens commerci brand dermatolog product journey current commerci stage compani
fortress compani shown figur journey launch product month sinc octob
dermatolog product luxamend wound cream manag superfici wound
minor abras dermal ulcer donor site first- second-degre burn radiat dermat launch
juli simultan compani launch ceracad steroid fragrance-fre ceramide-domin skin
emuls formul treat manag variou dermatolog condit journey also launch targadox
tetracycline-class antimicrobi sever acn octob compani state target top
prescrib dermatologist therebi expos dermatolog product total market
compani doubl sale forc repres gener net product revenu
million year three asset distribut nyse cardin nyse
hd smith acquir nyse
avenu atxi avenu found focus develop
intraven iv tramadol manag moder moder sever post-operative pain figur
tramadol synthet opioid well-establish efficaci safeti profil via two distinct mechan action
act weak opioid agonist inhibitor monoamin neurotransmitt posit efficaci
safeti data previous report use oral parenter form tramadol pain manag lead
approv eu studi provid solid foundat iv tramadol may
develop periop pain affect approxim patient fifth hour post-oper
second hour post-oper third hour
avenu current assess iv tramadol phase clinic trial patient undergo
bunionectomi recent announc posit top-lin data statist signific improv sum
pain intens differ hour primari endpoint compar placebo addit key
scott et al tramadol review use periop pain drug
gritti et al multicent trial compar tramadol morphin pain abdomin surgeri drug clin
tarradel et al respiratori analges effect meperidin tramadol patient undergo orthoped
magrini et al analges activ tramadol pentazocin post-operative pain clin pharmacol
singh et al preval acut post-op pain patient adult age-group undergo inpati abdomin
surgeri correl intens pain satisfact analges manag cross-sect singl institute-bas
secondari endpoint also met show dose respons treatment well toler
report treatment relat seriou compani plan begin second pivot phase studi iv
tramadol patient undergo abdominoplasti surgeri success iv tramadol would becom
schedul iv opioid us goal therapi provid bridg oral tramadol wide
use therapi also potenti displac schedul ii narcot mani patient lower potenti
substanc abus topic focu us healthcar system
cyprium therapeut privat cyprium focus develop novel therapi menk diseas
x-link copper metabol disord relat disord menk diseas rare pediatr diseas
character loss-of-funct mutat copper transport protein affect approxim
birth annual preval estim peopl infant often die age
three milder form diseas associ complic occipit horn syndrom
distal motor neuropathi march cyprium enter cooper research develop
agreement crada eunic kennedi shriver nation institut child human develop
nichd develop copper histidin inject treatment menk diseas shown
figur phase trial on-going complet phase i/ii studi demonstr improv
neurodevelopment outcom surviv patient menk diseas treat compani
discuss fda determin develop path toward submit new drug applic
nda
addit cyprium enter licens agreement nichd develop commerci adeno-
associ viru aav -base gene therapi refer method restor function
patient menk diseas current evalu preclin studi cyprium aim
ultim treat menk diseas combin orphan drug design
grant
cmv allogen stem cell
cmv kidney transplant
cmv liver transplant
patient art
helocyt privat helocyt develop novel immunotherapi primarili prevent treatment
cytomegaloviru cmv stem cell solid organ transplant recipi cmv common deadli viru
occur patient compromis immun system us eu annual incid rate cmv
allogen stem cell transplant solid organ transplant respect helocyt current
develop triplex multi-antigen cmv vaccin treatment cmv transplant phase result triplex
demonstr safeti toler allogen hematopoiet stem cell transplant hsct cmv-posit
recipi healthi shown figur triplex current on-going phase ii clinic trial
cmv allogen stem cell addit helocyt plan assess triplex indic outsid
post-transpl set helocyt also develop pentam preclin vaccin may capabl induc
broad neutral antibodi respons prevent congenit cmv
cellvat privat cellvat develop novel cellular therapeut treatment traumat brain injuri
us alon least hospit tbi across age group contribut
injury-rel million individu live long-term disabl result previou
translat us popul shown figur cellvat current develop
autolog bone marrow-deriv mononuclear stem cell treatment pediatr adult phase
ii clinic trial complet phase studi adult treatment demonstr preserv grey
matter white mater intracrani volum cerebr spinal fluid post month furthermor
seriou advers event relat harvest/infus stem cell except mild pulmonari toxic highest
dose altogeth structur preserv critic region adult brain correl function improv
patient downregul key inflammatori biomark transfus
la rosa et al mva vaccin encod cmv antigen safe induc durabl expans cmv-specif cell
frank et al traumat brain injuri unit state http //www cdc gov/traumaticbraininjuri
cox jr et al treatment sever adult traumat brain injuri use bone marrow mononuclear cell stem
novemb receiv fda regen medicin advanc therapi design
treatment sever data phase ii pediatr studi expect first half data
adult studi expect first half cellvat also conduct preclin studi assess
mechano-transduc cell therapi treatment sever adult children
well indic addit compani develop ceva-d novel mechano-transduct devic
may enhanc anti-inflammatori effect stem cell varieti sourc ceva-d design isol
potent sub-set cell without genet manipul therebi reduc number requir cell allogen
mnc pediatr
mnc adult
nextgen pediatr
nextgen adult
caelum bioscienc privat caelum clinical-stag compani develop treatment rare life-threaten
diseas lack effect therapi amyloid light-chain al amyloidosi character
accumul abnorm protein variou organ tissu bodi current cure
amyloidosi lead organ failur al amyloidosi common type system amyloidosi
incid approxim cases/million per compani lead asset novel antibodi
develop specif target al fibril induc dissolut amyloid deposit figur phase ia/ib
studi determin maximum toler dose futur studi
patient overal organ respons overal cardiac respons rate
overal renal respons rate organ respons rate stabl patient show organ progress
altogeth overal surviv rate month treatment march compani present data
intern symposium amyloidosi meet result show correl follow treatment
sustain decreas n-termin pro-brain natriuret peptid nt-probnp level
improv global longitudin strain gl patient cardiac al amyloidosi caelum enter
biopharmaceut manufactur agreement patheon nyse pthn phase clinic trial
expect begin earli
preclin gbm breast cancer metastat brain
clinic stage compani focus develop cancer
immunotherapi mustang primarili focus develop chimer antigen receptor t-cell car-t
therapi liquid solid tumor mustang in-licens technolog citi fred
hutchinson cancer center nci-design comprehens cancer center mustang
development pipelin shown figur compani lead program phase clinic studi
bpdcn b-cell non-hodgkin lymphoma indic target preclin candid includ
multipl myeloma prostat cancer pancreat cancer gastric cancer brain cancer metastat brain bladder
checkpoint therapeut checkpoint clinic stage oncolog compani focus
acquisit develop commerci non-chemotherapeut treatment patient solid tumor
compani current develop plethora fulli human target antibodi licens dr wayn
marasco laboratori dana-farb cancer institut shown figur licens antibodi includ
target program death-ligand glucocorticoid-induc tumor necrosi factor receptor gitr
carbon anhydras ix caix checkpoint plan develop antibodi monotherapi
combin
compani recent began expans phase phase trial antibodi
anti-gitr anti-caix antibodi preclin develop checkpoint also develop three
licens anti-canc therapi includ inhibitor epiderm growth factor receptor egfr mutat
bromodomain extra-termin bet protein bromodomain-contain protein poli adp-ribos
polymeras parp egfr parp inhibitor current phase develop phase clinic studi
assess bet inhibitor solid tumor expect begin note checkpoint enter
global collabor tg provid exclus right develop anti-
anti-gitr antibodi hematolog malign term agreement tg
made up-front payment provid potenti develop sales-bas mileston well tier
single-digit royalti net sale
fortress biotech fbio found fortress revers merger coronado
fortress obtain set oncolog asset licens like biopharmaceut subsidiari compani fortress
also development pipelin compani phase develop treatment
acut myeloid leukemia aml lysat abl activ donor nk cell call tumor activ
nk cell tank cell
fortress subset preclin stage subsidiari compani includ aevita privat tamid privat aevita
focus develop novel gene therapi complement-medi diseas aevita use aav-bas gene
therapi method restor product certain regulatori protein diseas high unmet medic
need atyp hemolyt urem syndrom ahu paroxysm nocturn hemoglobinuria pnh age-
relat macular degener addit tamid newest fortress subsidiari compani form base
three exclus licens agreement preclin aav gene therapi tamid lead asset current
develop mucopolysaccharidosi type mp rare disord character mutat idua
gene encod l-iduronidas protein associ mucopolysaccharidos aim restor l-
iduronidas defici patient mp goal improv long-term vision shown figur
tamid also pursu gene therapi treatment corneal transplant reject dysferlinopathi program
aevita tamid still preclin stage
figur fortress biotech preclin stage compani develop pipelin
ahu pnh
sinc found fortress establish total biopharma subsidiari compani total
commerci stage product double-digit number clinic pre-clin stage candid busi model
allow fortress provid experienc manag team resourc need develop product
candid event clinic trial failur impact fortress fraction subsidiari
focus develop product fortress well diversifi own fraction asset time
fortress continu add development-stag pipelin identifi candid exist new
subsidiari compani investor tress diversifi compani asset cover multipl diseas area
larg unmet medic need note fortress primarili develop stage current cash-
flow neg howev cash flow receiv fortress compani partial offset cost
fortress receiv fully-dilut outstand equiti annual fortress compani
fortress receiv royalti net sale fortress compani exclud journey
consolid revenu
fortress receiv annual consult fee fee increas million annual
subsidiari hold net asset greater million begin given calendar year
fortress receiv amount subsidiari common stock equal gross amount equiti
debt financ rais fortress compani
current valuat attribut limit valu fortress privat subsidiari mention fortress
ownership subsidiari compani shown figur fortress equiti ownership
mustang checkpoint avenu
therapeut atxi nation hold corpor nhld origo
acquisit corpor oacq notabl amount privat subsidiari sum-of-the-part
sotp analysi indic fortress cumul equiti valu public subsidiari compani roughli
million may howev million market cap cash cash equival cash deposit
restrict cash million debt million appear much valu current given
fortress privat subsidiari pipelin fortress fortress compani advanc
privat fortress compani becom publicli trade entiti expect could notabl valu gener
sharehold fortress biotech compani also like acquir new asset develop
fortress level within exist fortress compani new subsidiari compani
figur market valu fortress equiti compani
fortress
may outstand share basi
fortress exclus world-wide licens genemedicin privat develop commerci product
use genemedicin oncolyt adenoviru technolog term agreement fortress exclus
world-wide right three patent famili regard certain composit matter three patent famili includ
counterpart europ certain asian territori set expir respect grant us
counterpart first two patent famili set expir may extend later date
patent cover follow
recombin vector compris transcript regulatori sequenc oper link therapeut
method enhanc transduct effici recombin adenoviru express vector tumor
cell solid tumor
method co-express
fortress also exclus right intern patent applic pend us
foreign counterpart applic includ grant us patent correspond
nation phase applic direct stimul nk cell relat composit
method includ method treatment cancer condit patent famili in-licens
uclb expir januari prior potenti extens provid fortress exclus right
term uclb licens fortress made million up-front payment may requir make futur
regulatori commerci mileston payment roughli million net sale cndo-
commerci fortress grant sublicens third parti fortress oblig pay uclb
portion royalti receiv sub-license fortress also exclus right intern
applic pend us foreign counterpart applic direct toward
preserv activ nk cell relat composit method patent regard
former patent famili would expir juli prior potenti extens remain patent licens
specif subsidiari
chairman presid chief execut offic
dr rosenwald serv chairman presid ceo sinc decemb serv member
board director sinc octob sinc dr rosenwald serv co-portfolio manag
opu point partner llc opu asset manag firm life scienc industri prior
serv chairman paramount biocapit inc last year dr rosenwald
act biotechnolog entrepreneur instrument found recapit numer public
privat biotechnolog life scienc compani dr rosenwald receiv financ pennsylvania
state univers templ univers school medicin
mr weiss serv execut vice chairman strateg develop sinc januari serv
co-vic chairman board director sinc decemb sinc michael weiss serv co-
portfolio manag opu mr weiss co-found inc
publicly-trad biotechnolog compani focus acquir develop commerci drug
treatment b-cell malign mr weiss current serv tg execut chairman presid ceo prior
mr weiss chairman ceo keryx biopharmaceut inc kerx help
compani acquir develop lead drug zerenex well execut strateg allianc zerenex
jt tobacco inc torii pharmaceut co ltd mr weiss began profession career lawyer
cravath swain moor llp nyc mr weiss earn columbia law school financ
univers albani
ms hunter serv chief offic sinc june ms hunter year financi
oper experi array industri june appoint chief offic
ms hunter serv compani vice presid corpor control implement financi
oper process procedur polici facilit compani execut growth strategi
januari may ms hunter serv senior vice presid chief offic schochet
associ august januari ms hunter serv corpor control indevu
pharmaceut ms hunter held sever posit account manag vice presid
treasur stackpol corpor ms hunter hold econom union colleg
dr avgerino serv senior vice presid biolog oper sinc june dr avgerino join
compani abbvi inc vice presid humira manufactur scienc extern
partnership career formerli formerli basf bioresearch corpor
basf dr avgerino respons mani aspect biolog develop oper includ
humira oper franchis global biolog process manufactur scienc biolog
manufactur oper third-parti manufactur tenur dr avgerino led particip
develop numer clinic candid includ launch humira support expans
suppli chain billion annual global sale dr avgerino effort humira
recogn numer award includ prestigi abbott chairman award dr avgerino start
career inc subsequ join collabor research inc serv adjunct
associ professor chemic engin tuft univers dr avgerino author numer public
area biotechnolog product develop manufactur hold number product process
patent dr avgerino receiv biophys univers connecticut ph biochem
engin massachusett institut technolog
risk invest
consid invest fortress biotech medium risk invest fortress approv product
revenu gener compani compani shown recent growth sale although past perform
guarante futur success compani yet reach profit possibl fortress may need
seek addit financ futur addit guarante fortress fortress compani
clinic candid abl achiev regulatori approv target market despit signific time
financi invest mani market fortress subsidiari develop treatment
competit suscept price pressur unknown competitor may emerg
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
